Meeting
2020 Gastrointestinal Cancers Symposium
Complete neoadjuvant treatment for rectal cancer: A single institution experience.
Authors
John Baekey
Lifespan Cancer Institute, Providence, RI
John Baekey , Robert Brunault , Howard Safran , Rimini Breakstone , Matthew Vrees , Thomas A. DiPetrillo , Kara Lynne Leonard , Esther Yu , Khaldoun Almhanna
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Anal and Colorectal Cancer
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 148)
Abstract #
148
Poster Bd #
G12
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Complete neoadjuvant therapy in rectal cancer (CONTRE): A Brown University Oncology Research Group phase II study.
First Author: Kimberly Perez
Poster
2018 Gastrointestinal Cancers Symposium
VOLTAGE: Multicenter phase 1b/II study of nivolumab monotherapy and subsequent radical surgery after preoperative chemoradiotherapy with capecitabine in patients with locally advanced rectal cancer.
First Author: Yuichiro Tsukada
Poster
2017 ASCO Annual Meeting
A randomized phase II trial of consolidation chemotherapy after preoperative chemoradiation (preop CRT) versus CRT alone for locally advanced rectal cancer (LARC).
First Author: Sun Young Kim
Poster
2013 Gastrointestinal Cancers Symposium
Neoadjuvant capecitabine and oxaliplatin (XELOX) with bevacizumab for locally advanced rectal cancer.
First Author: Junichi Hasegawa